BioMed AG

The organizations say this collaboration uses the strengths of both to create a cutting-edge platform designed to uncover new insights into drugs, diseases, and biological networks by systematically exploring hidden biological patterns. The new discovery tool, to be developed on SAS Viya, a robust cloud-native AI and data platform, will, they say, combine Rejuvenate Biomed’s clinically validated AI-driven drug discovery capabilities with SAS’s extensive AI expertise. This collaboration is promising to enhance the efficiency and effectiveness of drug repurposing efforts, particularly for age-related diseases. “Our partnership with SAS amplifies the core strengths of both our R&D teams,” said Dr Ann Beliën, founder and chief executive officer of Rejuvenate Biomed. “By embracing this partnership and leveraging the capabilities of SAS Viya, we expect to meaningfully de-risk and accelerate the development of our internal portfolio while enhancing our discovery platform and partnering capabilities.” The low-code tool is designed for ease of use, allowing bioscience researchers with limited coding experience to harness powerful analytics. It will also serve advanced computational biology teams by providing a foundation for developing sophisticated analytics models. The tool will utilize SAS Visual Analytics for creating comprehensive reports, enabling researchers to derive actionable insights from complex biomedical data. “Our collaboration with Rejuvenate Biomed places us at the forefront of AI in biomedical research, reinforcing our commitment to supporting cutting-edge applied AI and analytics through SAS Viya,” said Udo Sglavo, vice president of Applied AI and Modeling at SAS. googletag.cmd.push(function () { googletag.display('text-ad1'); }); “Rejuvenate Biomed’s endorsement of SAS Viya to further develop their unique and proprietary drug discovery engine is a testament to our commitment to being the premier provider of structured and scalable AI solutions that enhance data analysis efficiency and accelerate the entire drug development life cycle.” This partnership not only equips Rejuvenate Biomed with the tools to scale its drug discovery platform but also strengthens its capacity to provide third-party services and expand its drug development pipeline. By utilizing AI to uncover non-trivial and novel biological interactions, Rejuvenate Biomed aims to accelerate the identification of potential therapeutic candidates and advance their development. Rejuvenate Biomed is a clinical-stage biotechnology company focused on developing therapeutics targeting the root causes of age-related diseases. Using its AI-enabled in silico CombinAge and in vivo CelegAge platforms, the company has built a pipeline of unique combination drugs addressing various age-related conditions, including neuromuscular, musculoskeletal, metabolic, cardiovascular, nephrological, and neurodegenerative diseases. Its lead asset, RJx-01, is phase 2-ready and has shown significant potential in treating sarcopenia. Rejuvenate Biomed said its disease-agnostic drug discovery platforms will continue to generate insights for future therapeutics, driving pipeline growth and fostering potential partnerships. Based in Belgium, Rejuvenate Biomed the company says it is committed to promoting healthy aging and advancing the science of age-related disease treatment.

The new research team at the BioMed X Institute in Heidelberg will develop a novel strategy to selectively target autoreactive plasma cells in autoimmune disease. Heidelberg, Germany and Paris, France--(News - June 26, 2024) - BioMed X, an independent German biomedical research institute, and Servier, an international independent pharmaceutical company, announce the start of a new research team at the BioMed X Institute in Heidelberg to develop innovative strategies for neutralizing autoreactive plasma cells in the context of autoimmune diseases. Current therapeutic strategies for autoimmune diseases primarily focus on broadly suppressing the immune response, with significant side effects. More importantly, none of these treatments address one of the root causes of the disease, the autoreactive plasma cells that produce antibodies targeting self-antigens. By exploring the deep biology of human autoreactive plasma cells to identify biomarkers that distinguish them from their physiological counterparts, this project aims to identify new therapeutic strategies to selectively eliminate these cells in patients suffering from autoimmune diseases. To view an enhanced version of this graphic, please visit: The new research team will be led by Dr. Eleonora Melzi, an experienced immunologist with expertise in B cell and antibody responses during infection. "A major limitation in the current treatment of autoimmune diseases is the absence of targeted therapies against autoreactive plasma cells, which are central to the pathogenesis of these conditions. Our research will focus on characterizing these cells to identify specific biomarkers that distinguish autoreactive cells from protective ones. Our final goal is to discover therapeutic targets that can selectively eliminate these harmful plasma cells. I am excited to apply my knowledge and experience in B cell biology to advance the understanding and treatment of autoimmune diseases at BioMed X." Ross Jeggo, Global Head of Neuroscience and Immuno-Inflammation Therapeutic Area at Servier: "BioMed X offers a unique opportunity, one that combines academic and industry research minds to develop innovative research strategies that can deliver transformative patient treatment options. As Servier looks towards its future, in neurology and beyond, partnerships like this with BioMed X will be invaluable in the identification of potential therapeutic solutions, including those involving autoimmune pathology." Christian Tidona, Founder and Managing Director of the BioMed X Institute: "Immunology - including autoimmunity - is one of our R&D focus areas at our BioMed X Institutes in Heidelberg, New Haven, and our XSeed Labs in Ridgefield, Connecticut. Before we started our collaboration with Servier, we were already hosting four immunology research teams at different stages of development in partnership with various international pharma partners. We are excited to extend our immunology research capabilities with this new project in the field of autoreactive plasma cells." About BioMed X BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world's brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds - academia and industry - and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun. BioMed X Press Contact Dr. Swathi Lingam Science Communication and Editorial Associate lingam@bio.mx To view the source version of this press release, please visit

TEL AVIV, Israel, April 18, 2024 /PRNewswire/ -- Biomed Israel, the premier international Life Science and HealthTech conference in Israel, will take place on May 21-23, 2024, at the David InterContinental Hotel in Tel Aviv, Israel. The event presents a unique opportunity for global healthcare and HealthTech leaders to experience Israel's innovative and vibrant life science and biomedical industry. For the 22nd consecutive year, Biomed Israel is the largest and leading meeting venue between healthcare professionals from Israel and their colleagues and partners from around the world, who come together for three days of intensive networking to discover business opportunities and promote partnerships. As in previous years, more than 100 Israeli life science companies, both promising startups and more established companies, will present and exhibit their innovative products and technologies. Co-Chaired by Ruti Alon, Founder and CEO of Medstrada, Ora Dar, PhD, Senior Expert, Medical Sciences and Health Innovation, and Nissim Darvish, MD, PhD, Managing General Partner, Eliraz Ventures, the conference will explore and aim to fuel the innovations and trends that are shaping the future of healthcare systems and life science. "In times of uncertainty, our determination to collaborate and aim to solve global unmet needs in healthcare serves as a beacon of hope and becomes our greatest strength," said Ruti Alon. "The first and foremost objective of Biomed Israel is to boost collaborations between the innovative HealthTech ecosystem in Israel and the global life science industry. Senior executives from multinationals, big pharma, medical devices, tech giants and international investors in the health industry come to Israel each May to "shop for" innovation in the field, in search for creative solutions, products and technologies, and the next big thing." "The conference will highlight the best of what Israel has to offer in a variety of areas and indications that coincide with the current trends that are of interest to the global life science industry. Experts will engage in thought-provoking discussions and presentations addressing a broad set of themes, from novel biological disease models to the vast amounts of available data that need to be curated and analyzed to turn into knowledge. These will be further coupled with discussion about concerns regarding global standards of living and the rising cost of healthcare. Whether it's chronic diseases, cognitive deficits, or cardiovascular and metabolic disorders, at this conference we will drill down to the interplay between specific trajectories and the therapeutic interventions designed to address them, both in terms of preventative measures and treatments," concluded Ms. Alon. The conference covers the entire scope of the life science industry, including biopharma, medical device, digital health, and diagnostic products and technologies, and will include the following sessions: Unlocking a new era in brain health innovation Why does cardiovascular disease remain the number ONE target for MedTech innovation? Digital Biomarkers & Digital Pathology: new tools to enhance therapy Liquid biopsy & Diagnostics: Getting closer to transforming early detection and disease management What can we do to make healthier aging a reality? Next generation of genetic medicine Is AI revolutionizing drug discovery and clinical development? Is it time to celebrate the rebound of the medical device sector? "NUTRItech" is the name of the game Evolving trends in cancer therapeutics The heart, the liver, the brain in concert: a year of revolutions in the cardiometabolic space Women's health: cutting-edge innovation to tackle collective pain points Digital health role in 2024 and forward Hospital at home: universities 'and hospitals' innovations Israeli medical contribution to breakthrough science and technology Advancements in the space of bio-convergence For plenary, keynote and session speakers For heads of sessions For preliminary agenda For registration Contact: Tsipi Haitovsky Global Media Liaison Biomed Israel Email: [email protected] Tel: +972-52-598-9892 SOURCE Biomed Israel